Your browser doesn't support javascript.
loading
Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration.
Toenges, Rosa; Lang, Fabian; Ghaffar, Rakhshinda; Lindner, Sarah; Schlipfenbacher, Vera; Riemann, Julia; Ajib, Salem; Kouidri, Khouloud; Cremer, Anjali; Weber, Bodo; Nguyen, Ngoc Thien Thu; Knoch, Antje; Vehreschild, Janne; Serve, Hubert; Bug, Gesine.
Afiliación
  • Toenges R; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany. RosaI_Toenges@DFCI.Harvard.edu.
  • Lang F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. RosaI_Toenges@DFCI.Harvard.edu.
  • Ghaffar R; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Lindner S; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Schlipfenbacher V; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Riemann J; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Ajib S; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Kouidri K; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Cremer A; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Weber B; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Nguyen NTT; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Knoch A; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Vehreschild J; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Serve H; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Bug G; Department of Medicine II, Hematology and Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Ann Hematol ; 2024 Sep 06.
Article en En | MEDLINE | ID: mdl-39237814
ABSTRACT
Patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) face an elevated risk of infection-related mortality, particularly during the pre-engraftment period. Although systemic antibiotic prophylaxis (SAP) is commonly employed during neutropenia, it is linked to disruptions in the intestinal microbiome, increasing the risk of graft-versus-host disease (GVHD), Clostridium difficile infection (CDI), and colonization with multi-drug resistant (MDR) bacteria. In our retrospective analysis, we evaluated the safety and efficacy of an exclusively interventional antibiotic treatment (IAT) compared to SAP in adult alloHSCT patients. In comparison to SAP, IAT resulted in a significantly reduced duration of antibiotic therapy (24 vs. 18 days, p < 0.001), although the cumulative incidence (CI) of bloodstream infections (BSI) by day + 100 post-HSCT was significantly higher in the IAT group compared to SAP (40% vs. 13%, p < 0.001). However, this did not lead to a significant increase in ICU transfers (13% vs. 6%, p = ns) or a higher CI of non-relapse mortality (NRM) at 3 years (11% vs. 10%, p = ns). With a median follow-up of 1052 days, the 3-year overall survival (OS) rates were 69% and 66% for the SAP and IAT cohorts, respectively (p = ns). The CI of acute GVHD grade II-IV (30% vs. 39%) at 100 days or chronic GVHD of any grade (50% vs. 45%) at 3 years did not differ significantly between the SAP and IAT groups. There was a tendency towards a higher CI of severe chronic GVHD in the SAP cohort (28% vs. 13%, p = 0.08). Our single center experience in conducting alloHSCT without antibiotic prophylaxis but with stringent guidelines for prompt antibiotic intervention demonstrated no disadvantages in terms of OS and NRM. IAT led to significantly reduced consumption of cefotaxime, carbapenem, and glycopeptide antibiotics. In conclusion, our findings suggest that replacing SAP with the proposed IAT procedure is both safe and feasible.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Ann Hematol / Ann. hematol / Annals of hematology Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Ann Hematol / Ann. hematol / Annals of hematology Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article